Real questions,
clinical answers.

Yes — and you're asking exactly the right question. LDL-C measures the cholesterol content inside LDL particles. ApoB counts the particles themselves. Every atherogenic particle — LDL, VLDL, IDL, Lp(a) — carries exactly one ApoB molecule. This means ApoB gives you a true particle count, which is what actually penetrates the arterial wall.

Here's why it matters: you can have an LDL-C of 138 with relatively few, large, buoyant particles (lower risk) or many small, dense particles (higher risk) — and the LDL-C number looks identical. ApoB distinguishes between those two scenarios. The 2026 ACC/AHA Dyslipidemia Guidelines now list ApoB as a preferred risk marker over LDL-C in patients with metabolic syndrome, diabetes, or elevated triglycerides.

While you're at it, ask for Lp(a) too — it's now a Class 1 recommendation for universal screening. It's genetic, it's highly atherogenic, and roughly 1 in 5 people have an elevated level without knowing it. It's measured once and doesn't change much over a lifetime.

Absolutely, yes — and your symptom pattern is textbook early insulin resistance. Fasting glucose and A1c are late markers. They don't rise until your pancreas can no longer compensate for insulin resistance by producing more insulin. By that point, you may have had significant insulin resistance for 5–10 years.

The marker you want is a fasting insulin level. From that, you calculate HOMA-IR: (fasting glucose in mg/dL × fasting insulin in µIU/mL) ÷ 405. A score above 2.0 suggests insulin resistance; above 2.9 is significant. Post-meal energy crashes, central adiposity, and brain fog are classic presentations even with a normal fasting glucose.

Ask your provider to add a fasting insulin to your next metabolic panel. It typically costs $20–40 and can identify risk a decade before diabetes develops. Diet modification, resistance training, and time-restricted eating have the strongest evidence for reversing early insulin resistance.

At 68 ng/mL, you are in what many clinicians and researchers consider the optimal range — not the toxicity range. True vitamin D toxicity (hypercalcemia, hypercalciuria) is typically associated with levels above 150 ng/mL and usually requires sustained doses above 10,000–40,000 IU/day for months. Your current level at 5,000 IU/day is a common, well-studied supplementation pattern.

The standard lab reference range (20–50 ng/mL) reflects minimum sufficiency to prevent deficiency disease, not optimal health outcomes. Most longevity-focused and functional medicine literature targets 40–60 ng/mL. Some researchers advocate up to 80 ng/mL. Your 68 sits comfortably in that zone.

That said, two important caveats: Are you taking K2 (MK-7 form, 100–200 mcg)? At doses above 2,000 IU, K2 is essential to direct calcium to bones rather than soft tissues. And have you had your serum calcium and urine calcium tested? Those are the actual safety markers — not the D level itself.

Your symptoms are classic hypothyroid presentation and a TSH of 3.2 alone does not rule it out. TSH alone is not a thyroid panel. TSH tells you what the pituitary is signaling; it doesn't tell you how much active thyroid hormone is actually reaching your tissues.

Request: Free T3, Free T4, Anti-TPO antibodies (thyroid peroxidase), and Anti-Thyroglobulin antibodies (TgAb). Anti-TPO and TgAb are the markers for Hashimoto's thyroiditis — autoimmune hypothyroidism — which can be present with a completely normal TSH for years before TSH rises. Many functional medicine and integrative clinicians also target a TSH of 1.0–2.0 as optimal, not the broad 0.4–4.5 reference range.

If antibodies are elevated, ask for a thyroid ultrasound. Heterogeneous texture on ultrasound is consistent with autoimmune thyroid disease even with currently compensated TSH.

Both NMN and NR are NAD⁺ precursors — they raise intracellular NAD⁺, which declines roughly 50% between age 20 and 60. The mechanistic rationale is strong; the human trial evidence is still emerging. NMN converts to NR before entering cells in most tissues, then to NMN again intracellularly — so they largely converge. The key differences are in pharmacokinetics and cost.

NR has more published human safety and efficacy data (Elysium, ChromaDex-sponsored trials). It raises blood NAD⁺ consistently at 300–500 mg/day. NMN has shown faster absorption in some studies and may have superior gut uptake via the Slc12a8 transporter in mice — but that transporter's role in humans is debated. Sublingual NMN bypasses gut metabolism and likely achieves better bioavailability.

For a 52-year-old starting out: 250–500 mg NMN or NR in the morning is a reasonable starting dose. Some protocols go to 1,000 mg NMN (David Sinclair's personal protocol). If you want objective data, baseline NAD⁺ blood testing is available through labs like Jinfiniti or iollo. That's the only way to know if it's actually working for you.

A ferritin of 11 ng/mL is clinically low — even if it technically falls within the lab's reference range. Reference ranges for ferritin are broad (12–150 ng/mL in many labs) because they reflect a statistical population average, not optimal function. Most functional medicine and hematology guidelines target ferritin above 50–70 ng/mL for women experiencing fatigue symptoms.

Ferritin is your iron storage marker. At 11, your iron stores are nearly depleted. Hemoglobin of 12.8 is borderline anemic — the body preserves hemoglobin as long as possible, so by the time it drops, your stores have been low for a while. Symptoms of iron deficiency often precede frank anemia: fatigue, cold intolerance, hair shedding, brain fog, and restless legs.

Before supplementing, your provider should also check a full iron panel: serum iron, TIBC, and transferrin saturation — plus consider ruling out a bleeding source. Do not self-supplement without this workup. Iron overload is harmful, and the form matters enormously: ferrous bisglycinate is best tolerated and most bioavailable; ferrous sulfate is the most common but causes significant GI side effects.